Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Cash: 2020-2025

Historic Change in Cash for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$28.6 million.

  • 4D Molecular Therapeutics' Change in Cash fell 1779.37% to -$28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$139.0 million, marking a year-over-year decrease of 57.69%. This contributed to the annual value of -$99.8 million for FY2024, which is 150.71% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Change in Cash of -$28.6 million as of Q3 2025, which was up 49.25% from -$56.4 million recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Change in Cash peaked at $157.7 million during Q2 2023, and registered a low of -$152.8 million during Q3 2021.
  • Moreover, its 3-year median value for Change in Cash was -$15.8 million (2025), whereas its average is -$345,091.
  • In the last 5 years, 4D Molecular Therapeutics' Change in Cash surged by 859.10% in 2023 and then plummeted by 1,779.37% in 2025.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Change in Cash stood at $62.0 million in 2021, then slumped by 190.22% to -$55.9 million in 2022, then soared by 52.51% to -$26.6 million in 2023, then plummeted by 43.78% to -$38.2 million in 2024, then slumped by 1,779.37% to -$28.6 million in 2025.
  • Its Change in Cash was -$28.6 million in Q3 2025, compared to -$56.4 million in Q2 2025 and -$15.8 million in Q1 2025.